Here, we provide evidence that endogenous IL-22 or biologically active, high circulating levels of IL-22 do not affect HFD-induced obesity and its metabolic consequences, although IL-22 is able to inhibit hepatic gluconeogenesis in hepatocytes. Here, IL22 is linked to obesity disorder.